A post was split to a new topic: Existing HIV Drug Reverses Muscle Aging by purging “Zombie Cell” Signals
Hey @NickG,
Any effects (good/bad) to report since you’ve been taking it for 2 months already? Have you done any lab tests recently(after starting Maraviroc) and what were the results? Thanks,
2 Likes
Walter_Brown, I assume that you’re using a 150 mg pill. If that is the case how do you manage to cut it into 10 segments?
2 Likes
It is available from India.
Axentri Maraviroc Tablets
"In India, Maraviroc is primarily sold under the brand name Axentri.
Brand Information
Manufacturer: Axentri is manufactured by Emcure Pharmaceuticals Ltd…
Availability: It is available in 150 mg and 300 mg tablets, typically sold in bottles of 60 tablets.’
3 Likes
A little about Emcure Pharmaceuticals. The lack of much export to more developed countries gives me a bit of concern about quality, as does the regulatory problems at that specific factory they produce the medicine at. I wish there were an easy, cost-effective way to have the medicine evaluated:
The following profile details the size, financial standing, and quality reputation of Emcure Pharmaceuticals Ltd. as of late 2025.
Quick Snapshot
- Industry Rank: 13th Largest in India (Domestic Sales)
- Market Cap: ~₹27,000 Cr ($3.2B USD)
- Primary Focus: Gynecology (#1 in India), HIV Antivirals, Cardiac, and Biologics.
1. Ranking & Financial Magnitude
Emcure is a significant Tier-1 player in the Indian pharmaceutical market (IPM), distinct for its heavy reliance on the domestic market compared to its export-heavy peers.
| Metric | Value / Rank | Context |
|---|---|---|
| India Rank | 13th | Based on domestic sales (MAT FY24). It is the 4th largest company in its specific “covered markets” (therapeutic areas it competes in). |
| Revenue (FY24) | ₹6,658 Cr (~$800M) | Domestic sales contribute approx. 48% of total revenue, which is higher than many Indian pharma peers who rely more on US exports. |
| Revenue (TTM) | ₹8,449 Cr (~$1B) | Trailing 12-Months as of Sept 2025. Growth has accelerated recently, driven by new product launches. |
| Market Cap | ~₹27,000 Cr | Listed on NSE/BSE in July 2024. Currently valued as a mid-cap pharma stock. |
| Key Segments | #1 in Gynecology | Also holds leadership positions in HIV (Antivirals) and Iron supplements. |
Note on Growth: Emcure has outperformed the Indian Pharmaceutical Market (IPM) growth rate in domestic sales over the last 3 years (CAGR of ~10% vs industry ~8%).
2. Quality Reputation & Regulatory Status
Emcure’s reputation is currently in a “Recovery and Redemption” phase. Historically plagued by severe regulatory issues, the company has made significant strides in 2024–2025 to clear its compliance record.
The “Red Flag” History (2015–2019)
- Warning Letters: The company suffered severe reputational damage due to US FDA warning letters in 2016 and 2019 for its Hinjewadi (Pune) facility.
- Issues Cited: Regulators cited data integrity breaches, poor aseptic processing techniques, and failure to investigate batch discrepancies. This effectively locked them out of significant US export opportunities for years.
Current Status: Significant Improvement (2024–2025)
As of December 2025, the company has successfully cleared multiple critical inspections, signaling a turnaround in manufacturing quality.
-
Gujarat (Kadu) Facility: Received “No Action Indicated” (NAI) status from the US FDA in December 2025 (Inspection Oct 2025). This is the highest compliance rating, meaning no objectionable conditions were found—a major “clean chit.” -
Sanand (Oncology) Facility: Concluded a US FDA Pre-Approval Inspection in July 2025 with Zero Observations.
-
Pune (API) Facility: Received 2 Observations (Form 483) in Feb 2025. However, this was later classified as VAI (Voluntary Action Indicated) in April 2025, meaning the FDA accepted their corrective plan and the facility is compliant enough to continue operations/exports.
Summary Verdict
- Commercial Strength: High. They are a dominant domestic force with a unique “brand-building” model rather than just generic commodities. They own the gynecological niche in India.
- Quality Risk: Moderate (Improving). While the historical data integrity issues were severe, the “Zero Observation” and “NAI” results in late 2025 suggest they have overhauled their quality management systems. They are no longer in the “danger zone” they were in 5 years ago.
Emcure manufactures Axentri (Maraviroc) at its primary solid oral dosage facility in Pune, Maharashtra .
Based on the product packaging and regulatory filings, the specific factory details are:
Manufacturing Location
- City: Pune, Maharashtra
- Facility Zone: Hinjewadi (a major IT and Biotech park in Pune)
- Specific Address:
Emcure Pharmaceuticals Ltd. Survey No. 255/2, Phase-I, Hinjewadi, Pune - 411 057, Maharashtra, India.
Facility Context
- Role: The Hinjewadi plant is Emcure’s headquarters and flagship facility. It is responsible for manufacturing the majority of their HIV antiretrovirals (ARVs) and solid oral formulations (tablets/capsules) for both the Indian domestic market and export to emerging markets.
Based on the manufacturing location of Axentri (Maraviroc) at the Hinjewadi, Pune facility, here is the specific quality and regulatory status for that site.
Facility Snapshot: Hinjewadi Phase-1 (Pune)
- Role: Emcure’s Headquarters & Flagship Facility (Solid Orals & Injectables).
- US FDA Status: Restricted / Official Action Indicated (OAI)
- Last Major Regulatory Action: Warning Letter (August 2019)
Detailed Quality Reports & Inspection History
Unlike Emcure’s newer facilities in Gujarat (which recently received a “clean” status), the Hinjewadi facility has a troubled regulatory history with the US FDA that has not yet been fully publicly resolved “close-out” as of late 2025.
1. The “Import Alert” (Ban) Status
- Status: The facility is under Import Alert 66-40.
- Meaning: This effectively bans most products manufactured at this site from entering the US market. The FDA placed this ban due to violations of “Good Manufacturing Practices” (GMP).
- The “Exception” for HIV Drugs: Crucially, the US FDA often grants exemptions for essential drugs where there is a shortage or medical necessity. Certain antiretrovirals (like Cidofovir and likely Maraviroc/Axentri) have historically been excluded from the ban, allowing them to be exported despite the facility’s overall non-compliant status.
2. Key FDA Observations (The “Red Flags”) The 2019 Warning Letter (which followed a 2015 ban) cited specific quality failures at Hinjewadi that impacted its reputation:
- Data Integrity: The most damaging finding was that data regarding sterility and quality testing was not reliable. The FDA cited instances where test results were potentially manipulated to pass batches that should have failed.
- Sterility Issues: For injectable lines, investigators found poor aseptic techniques (e.g., operators moving too quickly, disrupting sterile airflow) and contaminated media plates.
- Environmental Monitoring: Failure to properly monitor the manufacturing environment for bacteria/contaminants.
Current Verdict on “Axentri” Quality
- For the US Market: The facility is not considered fully compliant with US standards, but Axentri (as an HIV drug) likely falls under a “medical necessity” exemption allowing it to be sold.
Summary: While Emcure as a company has cleaned up its act in 2024–2025 (clearing inspections at its Sanand and Gujarat plants), the Hinjewadi facility where Axentri is made remains the “legacy problem” site with unresolved US FDA warning letters. The quality is sufficient for domestic approval but has historically failed to meet the higher bar of US regulatory clearance.
2 Likes
Am I meant to be cutting it into 10 segments?! 
. I’ve been taking 150mg twice daily (or a total of 300mg per day) for the last month. Feel fine and both my neuro- physiotherapist and personal trainer have noted fresh plasticity and progress.
2 Likes
Been on it for three weeks at 15-mg BID.
My question was based on your statement above of 15-mg BID several posts back. Now, should the dose be 15 mg BID or 150 mg BID? I’m not sure, but it seems to me that I saw somewhere in a RapAdmin post on Maraviroc that 15 mg BID or 30 mg daily would be appropriate.
2 Likes
Yes, I think it was 30mg but I’d cut 150 into four pieces and do it once per day to start and then maybe go twice per day. I wouldn’t go more than 75mg daily.
1 Like
Apologies, was a typo - will correct original post. Was meant to read 150mg. My mistake 
Have you ever tried LDN 3mg-4.5mg. A lot of people seem to have good results with it. I use it and it is an excellent medication for aches and pains (but never had covid so can’t speak to that). Maybe worth a shot.
1 Like
@desertshores, are you considering it? At almost 81, I’m watching this space carefully. Dose, frequency, mechanism, etc.
1 Like
Not just yet, I’ve already got so many meds I’m loath to start another one.
2 Likes
I’ve been exploring dosing approaches to try and replicate the effects from the mouse studies. The behavior of maraviroc in humans vs. mice is so different, a compounded micro dose may be needed. For now the approach I’m going with is to split 150 mg tablet into quarters (37.5 mg) and dose every 2 weeks. Here’s the analysis of that approach from Grok:
Dosing Interval to Approximate Mouse Study Approach
To address your question directly: yes, dosing frequency should ideally be based on the ratio of duration of inhibition to no inhibition to maintain a similar proportion of time under CCR5 inhibition, as this could better replicate the “pulsed” exposure profile in mouse studies where transient, short-lived inhibition (followed by extended troughs) led to senotherapeutic effects like reduced senescence and improved muscle/memory outcomes. However, this ratio must be adjusted for species differences in physiology (e.g., metabolism, half-life, and aging time scales) to ensure biological relevance—direct ratio matching without scaling could result in overly extended intervals that may not align with human senescence dynamics.
Mouse Exposure Profile Recap
- In key studies (e.g., 2025 senescence/sarcopenia models), mice received 10 mg/kg IP every 2 days (48-hour interval).
- Mouse half-life ~0.9 hours leads to rapid clearance: peak concentrations (~3600 ng/mL) drop below thresholds for meaningful inhibition (>30% occupancy, requiring ~793 ng/mL due to low mouse CCR5 affinity) within ~2 hours.
- Thus, ~2 hours of inhibition followed by ~46 hours of no inhibition per cycle (ratio 1:23, or ~4% time under inhibition).
- This pulsed profile (short bursts with long recovery) is thought to drive the “hit-and-run” senolytic-like effects without constant blockade.
Human Exposure Profile for Low Dose (37.5 mg Oral)
- A single 37.5 mg oral dose achieves peak concentrations ~17-28 ng/mL (scaled from 225 ng/mL for 300 mg single dose, adjusted for non-proportional PK and lower bioavailability ~20-23% at <100 mg).
- Human half-life ~14-18 hours (mean 16 hours) and high CCR5 affinity (KD ~0.089 ng/mL for 50% occupancy) result in prolonged high occupancy: >95% at peak, sustained >30% (threshold ~0.038 ng/mL) for ~5-6 days (time to drop from Cmax to threshold ~141 hours post-peak, approximating total duration above threshold).
- This creates a much longer inhibition phase than in mice, even at minimal doses.
Recommended Dosing Interval: Every 2 Weeks (Scaling the Ratio with Allometric Considerations)
- Direct Ratio Matching: To preserve the mouse 1:23 ratio (inhibition:no-inhibition), human no-inhibition would be ~115-138 days for a 5-6 day inhibition duration, yielding an interval of ~120-144 days (every 4-5 months). However, this ignores slower human metabolism and aging processes, potentially leading to insufficient pulses over time for cumulative senotherapeutic benefits.
-
Adjusted with Allometric Scaling for Time/Frequency: Pharmacological translation often scales time intervals (e.g., dosing frequency, half-life effects) by body weight^0.25 (~7-8 for mouse [0.025 kg] to human [70 kg]), as this accounts for metabolic rate differences and better predicts human PK/PD from animal data. Scaling the mouse 48-hour interval by ~7-8 gives ~14-16 days in humans.
- This maintains a scaled ratio: Human inhibition ~5-6 days (mouse 2 hours * ~18x half-life ratio, but capped by allometric ~7-8x), no-inhibition ~9-10 days (mouse 46 hours *7-8), ratio ~1:1.8 (adjusted from 1:23 to reflect faster mouse biology).
- Result: ~35-40% time under inhibition per cycle (higher than mouse’s ~4%), but biologically appropriate for slower human senescence turnover.
1 Like
Yes, thanks. I’ve been on 4.5mg LDN from Ageless RX for over a year now, unfortunately I’ve never experienced anything from it, good or bad. Staying on it just in case.
After 2 months the Maraviroc has improved my tachycardia and POTS symptoms slightly, although I still need the Metoprolol, and has also eliminated the “chirping” tinnitus that I had in my right ear, but unfortunately it hasn’t yet improved my general fatigue and weakness, exercise intolorance, or Post Exertional Malaise. I’ve one more month on it according to the current protocol, so I’m still hoping for further improvement.
5 Likes
Thanks for the update. If there is no improvement in the 1 month that is left, you could look into trying some new things to help fix those issues.
If your hormones are all in range, talk with your doctor about various stimulants or wakefulness-promoting agents such as:
modafinil, ritalin, vyvanse, buproprion, atomoxitine, adderall, dextroamphetamine etc.
Could also add other medications onto this if needed.
Not sure of all the supplements you take but you did mention tons and b vitamins, D3, astaxanthin, urolithin, ubiquinol etc…, but if you don’t use these other one’s already:
Could make a sport/energy protein drink with some whey (or vegan) protein powder.
Add in extra creatine around 5g. Beta alanine powder (carnosine production).
Extra tyrosine or phenylalanine for more catecholamines (dopamine, noradrenaline etc).
Use this shake with other food for a complete whole meal. Whatever you can stomach.
Other supplements to possibly take with the meal:
Omega 3 epa/dha are good. Extra vitamin b3 (niacinamide) is good (nad levels)
Multi vitamin & mineral.
Ginseng extract is decent. Coffee or caffeine pills.
Alpha gpc or citicoline for acetylcholine.
There’s more stuff but I don’t want to get too crazy.
4 Likes
Here’s the initial results from memory testing after a single 37.5 mg dose of maraviroc. I used the Moca Xpresso test which tests working memory. I have ADHD and therefore have baseline issues with working memory. To establish a baseline score, I did repeated testing to eliminate test familiarity gains. This resulted in a baseline score of 72. Two days after the initial dose of maraviroc, I repeated the test resulting in a score of 94. While there is the possibility of further familiarization gains, the test was noticeably easier this time, leading me to believe that there has been some improvement in working memory from the Maraviroc.
7 Likes
With aging the biggest decline I have noticed is in short-term working memory. I.e. remembering where did I put that tool, what I was going to do next, etc. Did you notice any improvements subjectively in your daily tasks and routines?
3 Likes
It’s a little too soon to say for sure, but I haven’t had any of those episodes of “what was I about to do?”
2 Likes
With regards to dosing, for sarcopina prevention, the dose and time extrapolated from the mouse studies is low (1/4 pill, or 37.5 mg, twice a week), but for demitia prevention, the doses currently being studied are much higher, 150 to 600 mg daily in post-stroke patients being studied in the CAMAROS and MARCH trials, whose results are expected to be published later in 2026. Perhaps lower dosing is all that’s needed for a healthy older person, but it seems likely that a minimum serum concentration will be required to pass the blood-brain barrier. Is see @fasterfour used only 37.5 mg dose. Any thoughts on dosing for the cognitive use case?
3 Likes
Good question. I think it might depend on your age and goals / situation. The MARCH trial is for mild cognitive impairment (MoCA Score ≤ 26), for people aged 50 to 86. Can it be helpful as a prophylactic? I think thats unknown, though it seems plausible. We have two variable to play with, frequency and dose.
While both trials use Maraviroc, they target different biological mechanisms:
- CAMAROS targets Neural Plasticity (Motor Cortex). It views CCR5 as a “brake” on learning that needs to be temporarily removed to allow the brain to rewire motor circuits.
- MARCH targets Neuroinflammation (White Matter). It views CCR5 as a driver of chronic inflammation that degrades white matter tracts over time, leading to dementia.
| Feature | CAMAROS Trial | MARCH Trial |
|---|---|---|
| Full Name | CAnadian MAraviroc Randomized Controlled Trial to Observe Stroke Recovery | MAraviroc for Recovery of Cognitive Health (Preventing Post-Stroke Dementia) |
| Primary Focus | Motor Recovery: Augmenting physical rehabilitation (walking & arm function) in early stroke survivors. | Cognitive Protection: Preventing post-stroke cognitive impairment (PSCI) and vascular dementia in subcortical stroke patients. |
| Dosing | 300 mg twice daily (BID). | 150 mg or 600 mg once daily. |
| Duration | 8 weeks of active dosing. | 12 months (52 weeks) of active dosing. |
| Status | Active / Recruiting (Phase II). | Active / Recruiting (Phase II). |
| Feature | CAMAROS Trial | MARCH Trial |
|---|---|---|
| Age Range | 18 years and older (Adults) | 50 – 86 years (Older Adults) |
| Time Since Stroke | 5 days – 8 weeks (Sub-acute phase) | 1 month – 24 months (Chronic phase) |
| Stroke Type | Ischemic Anterior Circulation (Cortical stroke affecting motor areas) | Subcortical Ischemic Stroke (Deep brain stroke affecting white matter) |
| Baseline Status | Motor Impairment (Hemiparesis requiring rehab) | Mild Cognitive Impairment (MCI) (MoCA Score ≤ 26) |
| Key Exclusion | HIV+, Severe Kidney Disease, Seizure Meds | Dementia (MoCA < 17), Large Cortical Infarcts |
Its interesting to look at the targeted endpoints in these trials as we think about how we might measure our own progress, or lack thereof, in trying this medication.
MARCH Trial Targeted Endpoints:
- Primary Endpoint: Change in global cognitive scores (neuropsychological battery) from baseline to 12 months.
-
Secondary Endpoints:
- MRI Neuroimaging: Progression of White Matter Hyperintensities (WMH) and cerebral atrophy.
- Inflammatory Markers: Reduction in systemic and CNS inflammation (e.g., CCR5 expression levels).
- Safety: Incidence of liver toxicity or severe adverse events over 1 year.
CAMAROS Targeted Endpoints:
- Primary Endpoint: Improvement in motor impairment as measured by the Fugl-Meyer Assessment (Upper Extremity) and walking speed (6-Minute Walk Test) at 6 months post-stroke.
-
Secondary Endpoints:
- Action Research Arm Test (ARAT): Measures specific grasp, grip, and pinch function.
- Cognitive scales: Montreal Cognitive Assessment (MoCA).
- Biomarkers: Serum levels of BDNF (Brain-Derived Neurotrophic Factor) and inflammatory cytokines.
2 Likes